Affylmmune Therapeutics, based in Natik, MA, develops cancer immunotherapies that extend CAR T cell activity to solid tumors using its “Tune & Track” platform. The platform tunes CAR T cell affinity to reduce toxicity and increase CAR T cell longevity while enabling in vivo monitoring via a proprietary tracking system. Its lead asset, AIC1000, is in a Phase 1 study for anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer. The company plans IND-enabling work for two additional pipeline candidates and to fund select drug discovery activities. Management includes Co-Founder & CEO Moonsoo Jin, Ph.D., and President & COO Eric von Hofe. Affylmmune intends to double headcount over the next nine months, focusing on expanding in-house discovery and leadership teams.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2021